State Street’s GT Biopharma GTBP Stock Holding History

State Street’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,666	Closed	-$20.4K	–	4383
2023 Q4	$20.4K	Hold	2,666	–	–	﹤0.01%	4341
2023 Q3	$19.3K	Hold	2,666	–	–	﹤0.01%	4446
2023 Q2	$25K	Sell	2,666 -63	-2%	-$653	﹤0.01%	4564
2023 Q1	$45K	Hold	2,729	–	–	﹤0.01%	4526
2022 Q4	$73.2K	Sell	2,729 -697	-20%	-$34.8K	﹤0.01%	4460
2022 Q3	$181K	Buy	3,426 +290	+9%	+$22.2K	﹤0.01%	4196
2022 Q2	$281K	Sell	3,136 -12,921	-80%	-$979K	﹤0.01%	4063
2022 Q1	$1.39M	Sell	16,057 -1,397	-8%	-$123K	﹤0.01%	3702
2021 Q4	$1.6M	Buy	17,454 +1,820	+12%	+$272K	﹤0.01%	3702
2021 Q3	$3.16M	Buy	15,634 +3,144	+25%	+$946K	﹤0.01%	3471
2021 Q2	$5.81M	Buy	+12,490	New	+$5.19M	﹤0.01%	3180

Other funds holding GTBP

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

State Street's GTBP Position: Q1 2024 in Review

State Street sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 2,666 shares — an estimated $20.4K sold.

State Street first reported a position in GTBP in Q2 2021 and held it in 11 quarters. The position peaked at $5.81M in Q2 2021. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

State Street reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
State Street sold 2,666 GT Biopharma shares in Q1 2024, an estimated $20.4K.
State Street first reported a position in GT Biopharma in Q2 2021 and held it in 11 quarters.
State Street's GT Biopharma position peaked at $5.81M in Q2 2021.
17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.